Dyslipidemia in ALS: good, bad, or unclear?
Albert
Steven M
SM
D000690:Amyotrophic Lateral Sclerosis / Q000453:epidemiology* / Q000209:etiology / Q000378:metabolism*; D002784:Cholesterol / Q000097:blood; D015897:Comorbidity; D050171:Dyslipidemias / Q000453:epidemiology* / Q000378:metabolism* / Q000503:physiopathology; D005234:Fatty Liver / Q000453:epidemiology / Q000378:metabolism; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects; D050356:Lipid Metabolism; D008077:Lipoproteins, LDL / Q000097:blood; D028361:Mitochondrial Diseases / Q000139:chemically induced / Q000150:complications / Q000503:physiopathology; D015995:Prevalence; D018401:Sample Size; D015996:Survival Rate
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D008077:Lipoproteins, LDL; D002784:Cholesterol